DaVita Inc. (DVA) incorporated in Delaware and headquartered in Denver, closed the week at $232.80. The company has a market capitalization of $14.9 billion. It provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. Despite Q1 2026 results that beat estimates, technical observations reveal a currently overheated state. The stock price is 35% above its rising 40 week moving average of $150.

The 14 week relative strength index is at 80% and well into overbought territory, while the weekly MACD-V indicator value at +209 is now at a level which is likely to provoke profit taking and a retracement toward the $200 area.

Disclaimer

Our opinions are not a recommendation to buy or sell a security. Your decision whether or not to open a transaction should be based on your own due diligence and not on any representation we make to you